[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100620238":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":18,"centralContacts":25,"locations":32,"responsibleParty":42,"collaborators":18,"id":46,"slug":47,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":18,"eligibilityCriteria":51,"healthyVolunteers":52,"sex":53,"minAge":54,"maxAge":18,"enrollmentInfo":55,"targetDuration":18,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":34,"whyStopped":18,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},{"fullName":5,"class":6},"Tri-Service General Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Intervention","EXPERIMENTAL","Initiation of Guideline-directed medical therapies, including angiotensin converting enzyme inhibitors (ACEi) or angiotensin II receptor blockers (ARB) , beta-blockers and sodium-glucose cotransporter 2 (SGLT2) inhibitors",[13],"Behavioral: Guideline-directed medical therapies",{"label":15,"type":16,"description":17,"interventionNames":18},"Control","NO_INTERVENTION","No Guideline-directed medical therapies",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":18},"BEHAVIORAL","Guideline-directed medical therapies","Guideline-directed medical therapies for patients at risk of heart failure, including angiotensin converting enzyme inhibitors (ACEi) or angiotensin II receptor blockers (ARB) , beta-blockers and sodium-glucose cotransporter 2 (SGLT2) inhibitors.",[9],[26],{"name":27,"role":28,"phone":29,"phoneExt":30,"email":31},"Wei-Ting Liu, M.D.","CONTACT","+886287923311","16118","wtliucv@gmail.com",[33],{"facility":5,"status":34,"city":35,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":18,"geoPoint":18,"contacts":39},"RECRUITING","Taipei","11490","Taiwan","TW",[40],{"name":27,"role":28,"phone":41,"phoneExt":30,"email":31},"+886-287923311",{"type":43,"investigatorFullName":44,"investigatorTitle":45,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"PRINCIPAL_INVESTIGATOR","Wei-Ting Liu","Clinical Doctor, Principal Investigator","100620238","ai-enabled-electrocardiogram-guided-guideline-directed-medical-therapy-on-incident-left-ventricular-dysfunction-a-target-trial-emulation-study-100620238",false,"NCT07355023","AI-Enabled Electrocardiogram-Guided Guideline-Directed Medical Therapy on Incident Left Ventricular Dysfunction: A Target Trial Emulation Study","Inclusion Criteria:\n\n* With an ECG followed by an echocardiogram within a 90-day interval\n* With preserved left ventricular ejection fraction (LVEF ≥ 50%)\n\nExclusion Criteria:\n\n* missing essential variables or ECG lead data\n* any prior LVEF \\\u003C 50%\n* loss to follow-up or death during the 90-day assessment window",true,"ALL","18 Years",{"count":56,"type":57},5000,"ESTIMATED","INTERVENTIONAL",[60],"NA","This multicenter retrospective study evaluates whether artificial intelligence-enabled electrocardiography (AI-ECG) can identify individuals at high risk for left ventricular dysfunction and whether targeted guideline-directed medical therapy can mitigate subsequent risk. Using a large multicenter cohort of patients with preserved left ventricular systolic function, the investigators applied an AI-ECG-based risk stratification approach and emulated a target trial to examine the association between guideline-directed therapies and the risk of incident left ventricular functional decline.",[63],"Left Ventricular (LV) Systolic Dysfunction",[65,66,67,68],"Artificial intelligence","Electrocardiogram","Deep learning","Left ventricular dysfunction","2026-01-12",{"date":71,"type":72},"2026-01-21","ACTUAL",{"date":74,"type":57},"2026-01-01",{"date":76,"type":57},"2026-01-15",{"name":5,"class":6},1]